{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:56:29Z","timestamp":1740174989012,"version":"3.37.3"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bulcan.2024.08.013","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T17:54:55Z","timestamp":1727114095000},"page":"1030-1037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Portrait mol\u00e9culaire dans les cancers des voies biliaires\u00a0: enqu\u00eate nationale de pratique aupr\u00e8s des plateformes fran\u00e7aises"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-4757","authenticated-orcid":false,"given":"Matthieu","family":"Delaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Sabourin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2024.08.013_bib0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-021-08261-1","article-title":"Cancer incidence and mortality trends in France over 1990-2018\u00a0for solid tumors: the sex gap is narrowing","volume":"21","author":"Defossez","year":"2021","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.bulcan.2024.08.013_bib0130","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2024.08.013_bib0135","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/cancers13112708","article-title":"Biomarkers in hepatobiliary cancers: what is useful in clinical practice?","volume":"13","author":"Boil\u00e8ve","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.bulcan.2024.08.013_bib0140","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.bulcan.2023.05.003","article-title":"Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy","volume":"110","author":"Rabehi","year":"2023","journal-title":"Bull Cancer"},{"issue":"11, Supplement","key":"10.1016\/j.bulcan.2024.08.013_bib0145","doi-asserted-by":"crossref","first-page":"11S28","DOI":"10.1016\/S0007-4551(22)00466-0","article-title":"Cholangiocarcinomes avanc\u00e9s et g\u00e8nes de fusion","volume":"109","author":"Mas","year":"2022","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2024.08.013_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2024.08.013_bib0155","doi-asserted-by":"crossref","first-page":"114000","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2024.08.013_bib0180","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1\u00a0mutation: the phase 3\u00a0randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.08.013_bib0185","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2\u00a0study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.08.013_bib0190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2024.08.013_bib0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132\u00a0trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.08.013_bib0200","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2\u00a0clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.08.013_bib0205","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2024.08.013_bib0210","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.08.013_bib0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02\u00a0phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.bulcan.2024.08.013_bib0220","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.08.013_bib0225","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bulcan.2024.08.013_bib0230","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158\u00a0study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.08.013_bib0235","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.bulcan.2024.08.013_bib0120","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11S","key":"10.1016\/j.bulcan.2024.08.013_bib0160","doi-asserted-by":"crossref","first-page":"11S3","DOI":"10.1016\/S0007-4551(22)00463-5","article-title":"Overview of biliary tract cancer management practices in France: results of the ACABi national survey","volume":"109","author":"Delaye","year":"2022","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2024.08.013_bib0165","doi-asserted-by":"crossref","first-page":"100324","DOI":"10.1016\/j.lanepe.2022.100324","article-title":"Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: a nationwide retrospective analysis","volume":"15","author":"Neuzillet","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.bulcan.2024.08.013_bib0170","doi-asserted-by":"crossref","first-page":"114018","DOI":"10.1016\/j.ejca.2024.114018","article-title":"Clinical care pathways of patients with biliary tract cancer: a French nationwide longitudinal cohort study","volume":"202","author":"Tzedakis","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.08.013_bib0175","doi-asserted-by":"crossref","first-page":"e2100484","DOI":"10.1200\/PO.21.00484","article-title":"Implementing the European Society for Medical Oncology Scale for clinical actionability of molecular targets in a comprehensive profiling program: impact on precision medicine oncology","volume":"6","author":"Martin-Romano","year":"2022","journal-title":"JCO Precis Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124003102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124003102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T14:52:54Z","timestamp":1730386374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124003102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0007455124003102"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.08.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Portrait mol\u00e9culaire dans les cancers des voies biliaires\u00a0: enqu\u00eate nationale de pratique aupr\u00e8s des plateformes fran\u00e7aises","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}